Docket Number:12A-1011214
Inventor:Steve Roffler, Yu-Cheng Su
IP Status:TW pending、PCT pending
Abstract:
We developed technology to allow isolation of higher affinity monoclonal antibodies in any established or newly formed hybridoma. Heavy chain class switch can also be conveniently performed simultaneously.
Fields of Application:
- Affinity maturation and class switch of monoclonal antibodies produced by existing hybridomas.
- Affinity maturation and class switch of monoclonal antibodies produced in newly formed hybridomas.
Advantages when compared to the existing technologies:
- ntibody affinity can be increased in any established or newly formed hybridoma without the need to perform any antibody cloning or genetic engineering.
- he technology does not depend on the antibody class and can be applied to hybridomas secreting IgM, IgG, IgA and IgE antibodies.
- he heavy chain of monoclonal antibodies can be switched to different classes, for example, an IgM antibody can be changed to IgG, without the need to perform any cloning of antibody genes.
- his technology can be simply performed in any lab without the need to learn antibody engineering technology.
- his technology can be used to increase the affinity or perform class switch of human monoclonal antibodies produced by hybridoma technology using transgenic human antibody mice.
- ntibody changes are limited to positions normally mutated in antibodies undergoing affinity maturation in vivo, indicating that the resulting antibodies will display low immunogenicity in patients.
Contact Person:Mei-Fang Lee / 886-2-2787-2503 / mflee@gate.sinica.edu.tw
